I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely.Our biotech Top Picks increased 137.6% last year with a 35.3% CAGR since 2017, along with a 23.2% CAGR for our core portfolio LTGP (CAGR performance as of March 20, 2026).To receive e-mail notifications for my public articles and blogs, ...

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., March 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado. AbbVie will present 24 abstracts at AAD, including one late-breaking pr ...

It's smart to seek dividend income from your investments because it can be used to help pay living expenses or to buy more stock. A solid dividend-paying stock to consider is pharmaceutical company AbbVie (ABBV +1.91%), which was spun off from Abbott Laboratories in 2013. The stock recently sported a 3.38% dividend yield, far above the average yield of 1.1% for stocks in the S&P 500.If you're looking for, say, $10,000 in annual dividend income, how many shares of AbbVie do you need to buy? Well, start by no ...

Key Takeaways Lilly's Mounjaro and Zepbound generated $36.5B in 2025, over 50% of total revenuesNew drugs and obesity pipeline, including orforglipron, are expected to fuel 2026 growthAbbVie's Skyrizi and Rinvoq drove strong sales, offsetting Humira erosion and supporting outlookEli Lilly (LLY) and AbbVie (ABBV) are leading, well-established U.S. drugmakers with multiple blockbuster therapies, strong R&D pipelines, significant market capitalizations and extensive global reach. Both maintain a solid presence ...

AbbVie (NYSE:ABBV) is among the best psychedelic stocks to buy in 2026. AbbVie (NYSE:ABBV) expanded its psychiatry pipeline with the acquisition of psychedelic compound bretisilocin from Gilgamesh Pharmaceuticals in 2025. It paid $1.2 billion for bretisilocin, a Phase 2 psychedelic drug candidate being developed as a treatment for major depressive disorder. AbbVie has a broad portfolio of approved drugs and drug candidates targeting diverse health issues. Copyright: katrintimoff / 123RF Stock Photo On M ...

Even the most dedicated income investors often avoid healthcare titles, especially those in the high-capital-expenditures pharmaceutical sector. As ever, though, we can find exceptions. Here's a brief look at two that buck the sector's general trend by not only paying dividends regularly, but also raising them on a consistent basis. Say hello to AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Will AI create the world's first trillionaire? Our team just released a report on the one little-known ...

AbbVie (ABBV 0.21%) is a top healthcare stock, but it isn't trading like one of late. This year, it's down 11%, and it has been underperforming the S&P 500, which is down only 4%. Investors have been bearish on healthcare stocks as a whole, with the Healthcare Select Sector SPDR ETF falling by 6% thus far. Concerns about healthcare reform and government cuts have been weighing on the sector.For investors, however, now can be an opportune time to buy low on a quality stock such as AbbVie. While it may not be ...

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers six different portfolios tailored for various income-seeking investors, including retirees or near-retirees [1] - The portfolios include two High-Income portfolios, a Dividend Growth Investing (DGI) portfolio, a conservative strategy for 401K accounts, a Sector-Rotation strategy, and a High-Growth portfolio [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for lower drawdowns and sustainable yields [2] - The service is designed to help investors create stable, long-term passive income [2]

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Follow Amneal Pharmaceuticals Inc Follow Novartis AG Follow Show more companies March 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potential risk ...

美容护理 2026 年 03 月 20 日 行 业 研 究 / 行 业 深 度 相关研究 证 券 研 究 报 告 联系人 证券分析师 行 业 及 产 业 王立平 A0230511040052 wanglp@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 全球业绩陆续企稳，中国市场曙光现 看好 ——国际化妆品医美公司 25 年业绩跟踪报告 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 投资案件 - ⚫ 2025 年全球美妆市场持续低速增长，受此影响，各大国际集团 2025 年收入端表现略 疲软，但整体开始企稳。据欧莱雅集团数据，2025 年全球美妆市场增速 3.5%，相比 24 年 4.5%的增长，以及 23 年 8%的高增长，需求端增速持续回落。需求端的疲软表 现，继续考验各国际集团的战略与适应能力，逆境行舟不进则退。20-24 年由于疫情、 宏观经济因素、中国市场疲软等多方面因素影响，各大 ...